BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20089653)

  • 21. Long-term maintenance of gp120-specific immune responses by genetic vaccination with the HIV-1 envelope genes linked to the gene encoding Flt-3 ligand.
    Sailaja G; Husain S; Nayak BP; Jabbar AM
    J Immunol; 2003 Mar; 170(5):2496-507. PubMed ID: 12594275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-covalent complexes of HIV gp120 with CD4 and/or mAbs enhance activation of gp120-specific T clones and provide intermolecular help for anti-CD4 antibody production.
    Manca F; Seravalli E; Valle MT; Fenoglio D; Kunkl A; Li Pira G; Zolla-Pazner S; Celada F
    Int Immunol; 1993 Sep; 5(9):1109-17. PubMed ID: 7902128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    Bogers WMJM; Barnett SW; Oostermeijer H; Nieuwenhuis IG; Beenhakker N; Mortier D; Mooij P; Koopman G; Remarque E; Martin G; Lai RP; Dey AK; Sun Y; Burke B; Ferrari G; Montefiori D; Martin L; Davis D; Srivastava I; Heeney JL
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combinatorial peptide library around variation of the human immunodeficiency virus (HIV-1) V3 domain leads to distinct T helper cell responses.
    Estaquier J; Boutillon C; Georges B; Ameisen JC; Tartar A; Auriault C
    J Pept Sci; 1996; 2(3):165-75. PubMed ID: 9231325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.
    Douagi I; Forsell MN; Sundling C; O'Dell S; Feng Y; Dosenovic P; Li Y; Seder R; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Feb; 84(4):1683-95. PubMed ID: 19955308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.
    Banerjee K; Andjelic S; Klasse PJ; Kang Y; Sanders RW; Michael E; Durso RJ; Ketas TJ; Olson WC; Moore JP
    Virology; 2009 Jun; 389(1-2):108-21. PubMed ID: 19410272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.
    Cerutti N; Killick M; Jugnarain V; Papathanasopoulos M; Capovilla A
    J Biol Chem; 2014 Apr; 289(15):10455-10465. PubMed ID: 24550395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An HIV Envelope gp120-Fc Fusion Protein Elicits Effector Antibody Responses in Rhesus Macaques.
    Shubin Z; Li W; Poonia B; Ferrari G; LaBranche C; Montefiori D; Zhu X; Pauza CD
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28404572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shaping T cell - B cell collaboration in the response to human immunodeficiency virus type 1 envelope glycoprotein gp120 by peptide priming.
    Steede NK; Rust BJ; Hossain MM; Freytag LC; Robinson JE; Landry SJ
    PLoS One; 2013; 8(6):e65748. PubMed ID: 23776539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    Wyatt R; Moore J; Accola M; Desjardin E; Robinson J; Sodroski J
    J Virol; 1995 Sep; 69(9):5723-33. PubMed ID: 7543586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies.
    Kim YB; Han DP; Cao C; Cho MW
    Virology; 2003 Jan; 305(1):124-37. PubMed ID: 12504547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
    J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
    Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
    J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.
    Qin Y; Shi H; Banerjee S; Agrawal A; Banasik M; Cho MW
    Retrovirology; 2014 Dec; 11():125. PubMed ID: 25527085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.